Use of Vitex agnus-castus in patients with menstrual cycle disorders: a single-center retrospective longitudinal cohort study.

Autor: Höller M; Bionorica SE, Kerschensteinerstr. 11-15, 92318, Neumarkt, Germany., Steindl H; Bionorica SE, Kerschensteinerstr. 11-15, 92318, Neumarkt, Germany., Abramov-Sommariva D; Bionorica SE, Kerschensteinerstr. 11-15, 92318, Neumarkt, Germany., Kleemann J; Bionorica SE, Kerschensteinerstr. 11-15, 92318, Neumarkt, Germany., Loleit A; Amstelveenseweg 122A2, 1075 XL, Amsterdam, The Netherlands., Abels C; Bionorica SE, Kerschensteinerstr. 11-15, 92318, Neumarkt, Germany., Stute P; Department of Obstetrics and Gynecology, Inselspital Bern, Friedbühlstrasse 19, 3010, Bern, Switzerland. petra.stute@insel.ch.
Jazyk: angličtina
Zdroj: Archives of gynecology and obstetrics [Arch Gynecol Obstet] 2024 May; Vol. 309 (5), pp. 2089-2098. Date of Electronic Publication: 2024 Feb 23.
DOI: 10.1007/s00404-023-07363-4
Abstrakt: Purpose: To evaluate clinical characteristics, quality of life (QoL) and effectiveness in patients with menstrual cycle disorders (MCDs) including abnormal uterine bleeding, dysmenorrhea and mastodynia/mastalgia related to premenstrual syndrome taking the Vitex agnus-castus (VAC) products Cyclodynon® or Mastodynon® in a real-world setting.
Methods: A single-center retrospective longitudinal cohort study (3 ± 1 months), using data obtained from healthcare data archive and telephone interviews. The main study variables were changes in bleeding, menstrual pain, breast tenderness and patients' QoL.
Results: Data from 1700 women with a mean age of 30.2 years (± 6.3) were analyzed. The most common MCDs were dysmenorrhea (43.8%) and mastodynia/mastalgia (21.1%). Three-month treatment with VAC extract substantially decreased the percentage of patients with irregular cycle (from 9.1% to 0.1%) and breast tenderness (from 39.9% to 0.8%). Improvement in bleeding intensity, frequency and menstrual pain was experienced by 83.4%, 79.2%, and 85.2% of the patients, respectively. When analyzed by disease category, these parameters improved in almost all dysmenorrhea patients, while they improved to a lesser extent in mastodynia/mastalgia patients. QoL improved in all aspects, but was reported by a higher proportion of dysmenorrhea patients compared to mastodynia/mastalgia patients. Treatment was overall well tolerated with a favorable safety profile.
Conclusion: These real-world data demonstrate the effectiveness of the VAC-containing products Cyclodynon® and Mastodynon® in the three-month treatment of MCDs, with a pronounced improvement in key disease symptoms and QoL. Intriguingly, while QoL was generally greatly improved, the response to VAC therapy varied depending on the type of underlying MCD.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: